Browse SYNPO2

Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Cytoplasm, cytoskeleton Cytoplasm, myofibril, sarcomere, Z line Cell junction, focal adhesion Note=Shuttles between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. In undifferentiated myoblasts strongly expressed in the nucleus, after induction of myotube differentiation is located to both nucleus and cytoplasm along acting filaments, and in differentiated myotubes is located at the Z lines. Upon stress redistributes from cytoplasm of myoblasts and myotubes to the nucleus. Nuclear import is KPNA2-dependent and promoted by phosphorylation by PKA and/or CaMK2, and inhibition of calcineurin. The nuclear export is XPO1-dependent (By similarity). Localized in a fiber-like pattern, partly overlapping with filamentous actin (PubMed:18371299). ; SUBCELLULAR LOCATION: Isoform 1: Cytoplasm, cytoskeleton Note=Localizes to induced actin bundles with contiguous staining. ; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, cytoskeleton Note=Localizes to induced actin bundles with punctuate staining. ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm, cytoskeleton Note=Localizes to induced irregular actin bundles with contiguous and punctuated staining. ; SUBCELLULAR LOCATION: Isoform 4: Cytoplasm, cytoskeleton Note=Localizes to induced actin bundles with punctuate staining. ; SUBCELLULAR LOCATION: Isoform 5: Cytoplasm, cytoskeleton Note=Localizes to induced actin bundles with contiguous staining.
Domain PF00595 PDZ domain (Also known as DHR or GLGF)
Function

Has an actin-binding and actin-bundling activity. Can induce the formation of F-actin networks in an isoform-specific manner (PubMed:24005909, PubMed:23225103). At the sarcomeric Z lines is proposed to act as adapter protein that links nascent myofibers to the sarcolemma via ZYX and may play a role in early assembly and stabilization of the Z lines. Involved in autophagosome formation. May play a role in chaperone-assisted selective autophagy (CASA) involved in Z lines maintenance in striated muscle under mechanical tension; may link the client-processing CASA chaperone machinery to a membrane-tethering and fusion complex providing autophagosome membranes (By similarity). Involved in regulation of cell migration (PubMed:22915763, PubMed:25883213). May be a tumor suppressor (PubMed:16885336). ; FUNCTION: Isoform 1: Involved in regulation of cell migration. Can induce formation of thick, irregular actin bundles in the cell body. ; FUNCTION: Isoform 2: Involved in regulation of cell migration. Can induce long, well-organized actin bundles frequently orientated in parallel along the long axis of the cell showing characteristics of contractile ventral stress fibers. ; FUNCTION: Isoform 3: Involved in regulation of cell migration. Can induce an amorphous actin meshwork throughout the cell body containing a mixture of long and short, randomly organized thick and thin actin bundles. ; FUNCTION: Isoform 4: Can induce long, well-organized actin bundles frequently orientated in parallel along the long axis of the cell showing characteristics of contractile ventral stress fibers. ; FUNCTION: Isoform 5: Involved in regulation of cell migration in part dependent on the Rho-ROCK cascade; can promote formation of nascent focal adhesions, actin bundles at the leading cell edge and lamellipodia (PubMed:22915763, PubMed:25883213). Can induce formation of thick, irregular actin bundles in the cell body; the induced actin network is associated with enhanced cell migration in vitro.

> Gene Ontology
 
Biological Process GO:0007015 actin filament organization
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0044089 positive regulation of cellular component biogenesis
GO:0051017 actin filament bundle assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0061572 actin filament bundle organization
Molecular Function GO:0003779 actin binding
GO:0042805 actinin binding
GO:0051371 muscle alpha-actinin binding
GO:0051393 alpha-actinin binding
GO:0071889 14-3-3 protein binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015629 actin cytoskeleton
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0030055 cell-substrate junction
GO:0031674 I band
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SYNPO2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SYNPO2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SYNPO2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2720.489
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3150.719
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2290.7
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3350.744
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0580.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6860.872
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8450.119
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8530.55
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9220.536
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7470.517
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.1790.128
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5020.0233
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SYNPO2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.21.420.80.00141
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.21.720.50.00342
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYNPO2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYNPO2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYNPO2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYNPO2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SYNPO2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SYNPO2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSYNPO2
Namesynaptopodin 2
Aliases MYOPODIN; genethonin-2; Synaptopodin-2
Chromosomal Location4q26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SYNPO2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.